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Abstract
Background: Interleukin-12 (IL-12) is well characterized to induce cellular antitumoral immunity by activation
of NK-cells and T-lymphocytes. However, systemic administration of recombinant human IL-12 resulted in severe
toxicity without perceptible therapeutic benefit. Even though intratumoral expression of IL-12 leads to tumor
regression and long-term survival in a variety of animal models, clinical trials have not yet shown a significant
therapeutic benefit. One major obstacle in the treatment with IL-12 is to overcome the relatively low expression
of the therapeutic gene without compromising the safety of such an approach. Our objective was to generate an
adenoviral vector system enabling the regulated expression of very high levels of bioactive, human IL-12.
Results: High gene expression was obtained utilizing the VP16 herpes simplex transactivator. Strong regulation
of gene expression was realized by fusion of the VP16 to a tetracycline repressor with binding of the fusion protein
to a flanking tetracycline operator and further enhanced by auto-regulated expression of its fusion gene within a
bicistronic promoter construct. Infection of human colon cancer cells (HT29) at a multiplicity of infection (m.o.i.)
of 10 resulted in the production of up to 8000 ng/106 cells in 48 h, thus exceeding any published vector system
so far. Doxycycline concentrations as low as 30 ng/ml resulted in up to 5000-fold suppression, enabling significant
reduction of gene expression in a possible clinical setting. Bioactivity of the human single-chain IL-12 was similar
to purified human heterodimeric IL-12. Frozen sections of human colon cancer showed high expression of the
coxsackie adenovirus receptor with significant production of human single chain IL-12 in colon cancer biopsies
after infection with 3*107 p.f.u. Ad.3r-scIL12. Doxycycline mediated suppression of gene expression was up to
9000-fold in the infected colon cancer tissue.
Conclusion: VP16 transactivator-mediated and doxycycline-regulated expression of the human interleukin-12
gene enables highly efficient and tightly controlled cytokine expression in human cancer. These data illustrate the
potential of the described adenoviral vector system for the safe and superior expression of therapeutic genes in
the treatment of colorectal cancer and other malignancies.
Published: 26 June 2007
BMC Biotechnology 2007, 7:35 doi:10.1186/1472-6750-7-35
Received: 24 February 2007
Accepted: 26 June 2007
This article is available from: http://www.biomedcentral.com/1472-6750/7/35
© 2007 Wulff et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Biotechnology 2007, 7:35 http://www.biomedcentral.com/1472-6750/7/35
Page 2 of 9
(page number not for citation purposes)
Background
IL-12 has a major impact in the modulation of cellular
immune response mechanisms. The heterodimeric
cytokine enhances the proliferation and activation of nat-
ural killer cells (NK-cells) and the maturation of activated
T lymphocytes to type 1 T helper cells (CD4+) and cyto-
toxic T lymphocytes (CD8+) [1-4] unveiling its potential
for the treatment of infectious [5,6] and malignant dis-
eases [7]. Induction of a cellular antitumoral immune
response is directed not only against the primary lesion
but also against distant organ metastases opening thera-
peutic options for those patients considered incurable at
the present time. Tumor regression at the treatment site as
well as in distant organ metastases was illustrated in 1997
utilizing a gene gun technique to incorporate plasmid
DNA into intradermal tumors in mice [8]. In this particu-
lar tumor model IL-12 resulted in a superior antitumoral
immune response and lasting systemic antitumoral
immunity as compared with a variety of other cytokines
(Interleukin-2, -4, -6, IFN-γ, TNF-α or GM-CSF). IL-12-
mediated antitumoral immune response was also illus-
trated in a variety of different murine tumor models [9-
14].
Systemic application of recombinant IL-12 resulted in a
broad and undirected stimulation of the cellular immune
system lacking antitumoral efficacy. Toxicity was mainly
contributed by the induction of interferon-γ with anti-
IFN-γ antibodies abolishing the lethal effect of systemic
administration of recombinant IL-12 in mice [15]. Inter-
feron-γ induction also contributes in part to the induction
of a cellular antitumoral immune response since anti-IFN-
γ antibodies diminish systemic antitumoral immunity
[14]. Nevertheless, studies with IFN-γ receptor-knockout
mice suggested an interferon-γ independent pathway of
IL-12-mediated antitumoral immunity [16].
In humans the maximum tolerable dose (MTD) of IL-12
was determined to be 0.5 µg/kg body weight after intrave-
nous administration [17,18] with reversion of advanced
cancer associated defects in T-lymphocytes and NK cells
[19]. Remarkably MTD was slightly lower after subcutane-
ous administration [20,21]. Repeated administration of
IL-12 resulted in an increasing tolerance (priming effect)
[20,22-24] which was in part due to increased STAT-4
(IFN-γ transcription activator) degradation.
In a phase II clinical trial repeated intravenous adminis-
tration of recombinant IL-12 within less than 7 days
resulted in leucopenia (65%), hyperbilirubinemia (47%),
elevation of transaminases (47%), dyspnoa (29%) and
lassitude (35%) with two fatalities due to hypovolemic
shock caused by hemorrhagic colitis and sepsis [17].
In Hodgkin's lymphoma repeated intravenous or subcuta-
neous administration of recombinant IL-12 resulted in a
21% response rate with partial (PR) and complete regres-
sion (CR) [25]. Repeated local administration of rhIL12 in
patients with T-cell lymphoma lead to an infiltration of
the tumor tissue with inflammatory cells resulting in PR
or CR in 50% of all cases [26]. IL-12 in patients with
melanoma produced similar response rates [27]. How-
ever, results in renal cell and ovarian carcinoma were
rather disappointing [28-31]. Colombo described in 1996
that the concentration of IL-12 at the tumor site might be
crucial for the establishment of systemic antitumoral
immunity [32].
With the development of vector systems, lasting as well as
local expression of therapeutic genes have become feasi-
ble. Consequently, murine cancer cells either modified by
IL-12 encoding plasmids or retrovirally transduced ex vivo
[32-34] were able to immunize against the native cancer
cell line and to protect against the tumor cells in consecu-
tive challenge experiments. Even though direct intratu-
moral injection of IL-12 encoding plasmids resulted in
significant immune response in different animal models
[16,35,36], antitumoral response in a clinical trial
remained marginal with no cure or long term immunity
[37]. Poor transduction efficacy of plasmid vectors was
overcome by the use of adenoviral vectors. Intratumoral
injection of IL-12 encoding recombinant adenoviral vec-
tors in mice resulted in a specific immunity against breast
cancer and colon cancer [38,39]. Adoptive immunotrans-
fer illustrated T-cell mediated, long term systemic immu-
nity [40].
Gene therapeutic approaches utilizing the coexpression of
both subunits for the generation of bioactive IL-12 were
compromised by the formation of inhibitory p40
homodimers. This interference was prevented by the
introduction of IL-12 fusion genes [34,41-43]. The poten-
tial of these constructs integrated in adenoviral expression
systems for the treatment of gastrointestinal tumors was
illustrated recently [44,45].
Considering the potential toxicity related to the expres-
sion of IL-12 and the necessity of high intratumoral con-
centrations, the scope of this study was to construct an
adenoviral vector for highly efficient and regulated expres-
sion of a human single-chain IL-12. A modified E. coli
operator system was utilized for tetracycline suppressible
expression. High gene expression was enabled by the use
of a VP16 herpes simplex virus transactivator fused to the
E. coli Tet-repressor. Positioning of the trans-activating
fusion protein was realized by Tet-operator upstream of
the gene of interest [46]. This system was further
enhanced by integration of a bidirectional promoter also
expressing the transactivator in the absence of doxycyclineBMC Biotechnology 2007, 7:35 http://www.biomedcentral.com/1472-6750/7/35
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[47]. In the presence of low concentrations of doxycycline
the fusion protein immediately dissociates from the Tet-
operator thru binding of doxycycline to the Tet-repressor
domain with drastic reduction of VP16 mediated gene
expression.
Results
Construction of suppressible vectors for the expression of 
human IL-12
The adenoviral expression plasmid pAd.3r-hscIL-12 was
constructed as described, and corresponding recombinant
E1/E3 deleted adenoviral vectors were generated by cal-
cium phosphate mediated cotransfection with pBHG10 in
293-cells (figure 1). Plaques were purified and the adeno-
virus was amplified in 293-cells. The adenoviral titer was
determined utilizing standard plaque assay procedures.
Dox-dependent expression of human single-chain IL-12
We were able to illustrate the high adenoviral transduc-
tion efficacy in HT29 human colon cancer cells in previ-
ous publications [45,49,50]. These cells were infected
with Ad.3r-hscIL12 at an m.o.i. of 10 followed by incuba-
tion for 48 hours at various concentrations of doxycycline.
Human single-chain IL-12 was then determined in the cell
lysate and the cell free culture supernatant. Substantial
suppression was obtained at doxycycline concentrations
as low as 3 ng/ml with maximum suppression levels of
2200-fold for IL-12 in the supernatant and 5000-fold in
the cell lysate at 30 ng/ml doxycycline (figure 2). In the
absence of dox, infection at an m.o.i. of 10 resulted in 2%
IL-12 in relation to total soluble cellular protein (data not
shown).
Western blot analysis revealed significant suppression of
TetR as detected with a TetR monoclonal antibody [46],
illustrating down regulation of the transactivator propor-
tional to the suppression of IL-12 expression in the pres-
ence of doxycycline (figure 3).
Comparison of bioactivity
Bioactivity of adenovirally-expressed human single-chain
IL-12 was compared with purified heterodimeric p40/p35
standard in order to estimate the biological response in a
clinical setting. Bioactivity was first evaluated by IFN-γ
induction in human mononuclear cells after conditioning
with CD3- and CD28- antibodies. Pretreated MNC were
then incubated with hscIL-12 from the supernatant of
adenovirally infected HT29 cells or with equivalent con-
centrations of a human heterodimeric IL-12 WHO-stand-
ard. Twenty-four hours after incubation at 37°C,
Doxycycline dependent IL-12 expression Figure 2
Doxycycline dependent IL-12 expression. Production 
of human interleukin-12 after infection of HT29 human colon 
cancer cells with Ad.3r-scIL12 at various concentrations of 
doxycycline.
Vector construction Figure 1
Vector construction. Construction of recombinant adeno-
viral vectors expressing human IL12 under control of doxy-
cycline by calcium phosphate-mediated coprecipitation of the 
corresponding plasmids in 293 cells. VP16: Herpes simplex 
virus transactivator gene, TetR: Tetracycline repressor gene, 
TKmin: Thymidine kinase minimal promoter, TetO7: Tetra-
cycline operator (seven copies), CMVmin: Cytomegalovirus 
minimal promoter, hscIL-12: human single-chain IL-12 gene, 
Amp R: ampicillin resistance gene, ITR: inverted terminal 
repeat, pA: poly-A from the bovine growth hormone gene.
Doxycycline dependent tTA expression Figure 3
Doxycycline dependent tTA expression. Western blot 
analysis illustrates the positive feedback loop with dose 
dependent suppression of the tTA fusion protein in the pres-
ence of doxycycline.BMC Biotechnology 2007, 7:35 http://www.biomedcentral.com/1472-6750/7/35
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expressed human interferon-γ was quantified by ELISA
(figure 4). Bioactivity profiles did not reveal a significant
difference. Interferon-γ induction was observed at IL-12
concentrations as low as 10 pg/ml with maximum induc-
tion at 1 ng/ml. ED50 was estimated to be 54 – 64 pg/ml
IL-12 resulting in the induction of interferon-γ at 3000 pg/
ml. Basal induction of interferon-γ in the absence of IL-12
was 1400 pg/ml, mainly due to prestimulation of MNC
with CD3- and CD28-antibodies.
To further delineate whether the IFN-γ production was
induced by IL-12, pre-stimulated MNC were incubated
with a) native medium, b) heterodimeric IL-12, or c) viral
IL-12 for 24 hours and brefeldin A for 20 hours to prevent
the release of intracellular proteins including IFN-γ. The
MNC were subsequently labeled by surface staining with
fluorochrome-conjugated mAb's detecting CD3-APC/
CD8 and CD69 followed by intracellular labeling with an
anti-IFN-γ -FITC mAb and analyzed by flow cytometry.
Recently activated T4- and T8-cells as defined by the
expression of CD69 were analyzed for their IFN-γ produc-
ing profile. A representative IFN-γ expression analysis is
shown in Figure 5A.
Basal production of IFN-γ was 5.81% ± 0.18% (CD4+)
and 9.75% ± 0.58% (CD8+). Incubation with standard-
ized heterodimeric human IL-12 resulted in 12.80% ±
0.42% (CD4+) and 21.08% ± 0.63% (CD8+) activation,
incubation with adenovirally produced human single-
chain IL-12 resulted in 12.05% ± 0.52% (CD4+) and
19.68% ± 0.90% (CD8+) production of IFN-γ. Both IL-12
preparations resulted in highly significant activation of
CD4+ and CD8+ cells (p < 0.0001 each) with no signifi-
cant difference in between heterodimeric IL-12 and sin-
gle-chain IL-12 (CD4+: p = 0.124, CD8+: p = 0.092)
concluding equal bioactivity for both cytokines (figure
5B).
Coxsackie-adenovirus receptor expression and adenoviral 
transduction in human colon cancer
Demonstrating high adenoviral transduction efficiency in
a variety of human colon cancer cell lines [45], the ques-
tion remained whether native human cancer tissue shows
equal susceptibility towards adenoviral infection. Since
adenoviral infection is mainly mediated by the Coxsackie-
Adenovirus receptor (CAR), human colon and colon can-
cer tissues were stained for CAR expression. As illustrated
in figure 6, normal colon epithelium as well as human
colon cancer cells revealed high expression of the CAR
using a monoclonal CAR-antibody and APAAP staining
with no expression in the adjacent tissue. Staining apply-
ing a detection system based on horseradish peroxidase
FACS analysis Figure 5
FACS analysis. FACS analysis of IFN-γ in CD3-gated MNC 
after preactivation by anti-CD3 and CD28 (negative control), 
additional stimulation with standardized heterodimeric 
human IL-12 (WHO IL12-standard) and adenovirally pro-
duced single-chain IL-12 (p40.linker.p35). A: comparison of 
representative samples, B: average of activated CD4+ and 
CD8+ T-lymphocytes (n = 3).
Comparison of bioactivity Figure 4
Comparison of bioactivity. Comparison of interferon-γ 
induction by incubation of mononuclear cells (MNC) with 
either adenovirally generated single-chain human interleukin-
12 or purified standardized heterodimeric human inter-
leukin-12 as quantified by ELISA.BMC Biotechnology 2007, 7:35 http://www.biomedcentral.com/1472-6750/7/35
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resulted in identical distribution (data not shown). Figure
7 illustrates transgene expression after infection of human
colon cancer specimens with doxycycline suppressible
adenoviral vectors. Luciferase and human IL-12 were sig-
nificantly expressed in human colon cancer tissue in the
absence of doxycycline. Addition of dox at a concentra-
tion of 2 µg/ml resulted in a 1200-fold suppression for
non-secreted luciferase and 9700-fold suppression for
secreted single-chain human IL-12.
Discussion
Recent clinical trials utilizing recombinant IL-12 in the
experimental treatment of human cancer illustrate the
potential hazards of these approaches. Severe side effects
such as hemorrhagic colitis and sepsis indicate the unac-
ceptable risk associated with systemic and repeated
administration of recombinant IL-12 in the treatment of
cancer [17]. Local application is limited by the short half-
life of the cytokine and showed some efficacy only in a
sparse number of tumor entities. Therefore, local expres-
sion of an IL-12 gene is a promising approach to avoid
such problems. Vector systems for the expression of
human IL-12 did not result in significant clinical response
yet, which is most likely due to weak transgene expres-
sion.
We were able to construct adenoviral vectors addressing
these issues by incorporation of a highly potent and dox-
ycycline-regulated transactivator for the expression of
human single-chain IL-12. Infection of human colon can-
cer cells (HT29) at an m.o.i. of 10 resulted in the expres-
sion of 8000 ng/106 cells in 48 h. To our knowledge, these
expression levels exceed any adenoviral vectors expressing
human IL-12 as well as stably transduced cell lines pub-
lished so far. Doxycycline concentrations as low as 30 ng/
ml resulted in suppression levels of up to 5000-fold. With
peak concentrations of 2.6 µg/ml 2 hours after oral appli-
cation of 200 mg doxycycline and average serum levels of
1.11 µg/ml after 100 mg doxycycline daily [51], suitable
concentrations of doxycycline are quickly obtainable for
efficient and timely suppression of transgene expression.
Addition of doxycycline to the drinking water completely
abolished the otherwise lethal effect of these systemically
administered murine IL-12 expressing vectors in mice
(Block et al., Manuscript submitted).
Interferon-γ induction in human mononuclear cells after
incubation with adenovirally expressed human single-
chain IL-12 did not differ from induction with purified
p35/p40 heterodimer at various concentrations. These
results together with the comparative FACS analysis show
similar bioactivity. Inhibition of bioactivity through the
formation of p40 homodimers was avoided by expressing
a IL-12 fusion protein rather than the separate subunits
e.g. by utilizing an internal ribosome entry site [52,53].
Furthermore, the human single-chain IL-12 contains a
secretory leader domain, resulting in efficient secretion
Ex vivo expression of luciferase and IL-12 Figure 7
Ex vivo expression of luciferase and IL-12. Luciferase 
and IL12 expression after ex vivo infection of human colon 
cancer biopsies with Ad.3r-luc or Ad.3r-hscIL12 in the pres-
ence (2 µg/ml) or absence of doxycycline.
CAR expression in human tissue Figure 6
CAR expression in human tissue. Expression of the cox-
sackie adenovirus receptor (CAR) in biopsies of normal 
human colon (upper panel) and human colon cancer (lower 
panel). Red staining of CAR after reaction with a monoclonal 
anti-CAR antibody and an APAAP detection system.BMC Biotechnology 2007, 7:35 http://www.biomedcentral.com/1472-6750/7/35
Page 6 of 9
(page number not for citation purposes)
independent of posttranslational processing and p35 sub-
unit glycosylation [54,55].
Adenoviral transduction of human tissue requires the
expression of the coxsackie adenovirus receptor (CAR)
with vector internalization depending on alphavbeta3-
and alphavbeta5-integrins. Expression of the CAR was
shown in human colon epithelium as well as colon cancer
illustrating the feasibility of adenoviral transduction and
adenovirally mediated transgene expression. Adenoviral
infection of freshly derived human colon cancer biopsies
with 3*107 p.f.u. demonstrated efficient ex vivo transgene
expression as well as highly significant doxycycline-medi-
ated suppression in tumor tissue. Colon cancer differenti-
ation dependent CAR expression and consecutive
transgene expression remain to be determined and is cur-
rently under investigation.
These data further support the use of doxycycline-sup-
pressible, highly efficient adenoviral vector systems for
the treatment of human cancer. Vector related toxicity
could probably be avoided by applying a significantly
lower viral dose since transgene expression within these
new promoter systems was shown to be more than 4000-
fold higher as compared with the CMV-promoter com-
monly used in clinical trials. Tumor regression and sys-
temic immunity after high intratumoral human IL-12
expression have to be addressed in a clinical setting. Even
though oral administration of doxycycline can dramati-
cally reduce IL-12 expression and related toxicity in mice,
doxycycline mediated suppression of IL-12 expression in
humans remains to be investigated. Serum half life of
recombinant human IL-12 was determined to be 5 to 21
hours [18,20,23,56], thus possibly requiring additional
precautions such as the temporary application of neutral-
izing anti IL-12 or interferon-γ antibodies in order to inac-
tivate circulating cytokines.
Conclusion
With expression levels exceeding the widely used viral
CMV-promoter, combined with tight regulation of gene
expression by low concentrations of doxycycline, we are
confident that these adenoviral vectors will add to the fea-
sibility and safety in the immunotherapy of colorectal
cancer as well as other malignancies.
Methods
Cell lines
The 293-cell line was utilized for virus generation and
amplification. 293-cells were maintained in HGDMEM
(Gibco, Rockville, MD). HT29-cells were kept in McCoy
5A medium (Gibco). Human mononuclear blood cells
(MNCs) were cultivated in RPMI1640 medium (Gibco).
All cell culture media were supplemented with 10% fetal
bovine serum (Gibco) or certified tetracycline free fetal
bovine serum (Clontech, Palo Alto, CA), 1% L-glutamine
and 1% penicillin/streptomycin (Gibco).
Human colon cancer specimen
In accordance with national ethical guidelines issued by
the German research foundation patients were informed
about the study and gave their written consent at a mini-
mum of 24 hours prior to surgery. Colon cancer speci-
mens were removed according to standard surgical
procedures. At least 8 colon cancer biopsies were taken
from the vital area of each freshly prepared human colon
cancer tissue utilizing a medium size endoscopic biopsy
forceps. These samples were washed three times with PBS
prior to ex vivo transduction with viral vectors.
Construction of adenoviral expression plasmids
Preparation of plasmid DNA was performed utilizing a
modified alkaline lysis protocol followed by purification
through anion exchange column (Qiagen, Valencia, CA).
Plasmid DNA was propagated in DH5a E. coli. Restriction
endonucleases were obtained from Boehringer Man-
nheim (Ingelheim, Germany) and New England Biolabs
(Ipswich, MA). The plasmid pSFG-hIL12.p40.linker-
delta.p35 containing a human IL-12 fusion protein, was
kindly provided by R.C. Mulligan (Children's hospital,
Boston, MA) [42]. The backbone plasmid pAd.3r.pA was
obtained by digestion of pAd.CMV.pA [45] with XbaI,
blunting and SalI in order to remove the CMV promoter,
the multiple cloning site, and the polyA. The previously
described bicistronic promoter element was then released
from pBIG3r after digestion with PvuII and SalI and
ligated into the adenoviral expression plasmid. The cDNA
encoding for human single-chain IL-12 (hscIL12) was
released from pSFG-hIL12.p40.linker-delta.p35 through
digestion with NcoI, refilling with T4 polymerase and sub-
sequent digestion with NheI. pAd.3r.pA was digested with
BamHI, refilled and digested with SpeI with ligation of the
previously released hscIL12 encoding cDNA in between 3r
and the poly A. The resulting adenoviral expression plas-
mid pAd.3r.hscIL-12 contains the cDNA encoding for a
human IL-12 fusion protein under control of a bidirec-
tional, doxycycline-suppressible promoter element, 5'-
flanked by base pairs 1 to 456 and 3'-flanked by base pairs
3346 to 5864 of the Ad5 genome. Minimal TK-promoter-
driven expression of the tTA was antiparallel and minimal
CMV-promoter-driven expression of the human single-
chain IL-12 gene was parallel to adenoviral E1 transcrip-
tion. The complete expression cassette was sequenced and
a base exchange repair performed at position 4059 (C/T)
by PCR.
Generation and amplification of the corresponding 
adenoviral vector
Recombinant, E1- and E3-deleted adenoviral vectors were
generated by calcium phosphate mediated coprecipita-BMC Biotechnology 2007, 7:35 http://www.biomedcentral.com/1472-6750/7/35
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tion and homologous recombination of pAd.3r.hscIL12
with pBHG10 in 293-cells as described elsewhere [48].
Adenoviral vectors were propagated in 293-cells and puri-
fied by CsCl density gradient centrifugation. Titration of
the purified virus was performed by plaque assay. The
obtained titer for Ad.3r.hscIL12 was 3.6*109 p.f.u./ml.
Viral DNA was isolated using the DNA Blood Mini Kit
(Qiagen) and sequencing of the insert was done with an
ABI 377 Sequenator (Perkin Elmer, Norwalk, CT) after
asymmetrical amplification and labeling with BigDye Ter-
minator Cycle Sequencing Mix (Applied Biosystems, Fos-
ter City, CA).
Transfection and quantification of transgene expression
HT29 human colon cancer cells were seeded in six-well
plates at a concentration of 106 cells/well 6 hours prior to
infection. Tumor cells were infected in triplicates with
purified recombinant adenovirus in 500 µl serum-free
media for 1 hour followed by incubation with complete
media and different doxycycline concentrations for
another 48 hours. Human single-chain IL-12 was quanti-
fied in cell-free culture supernatant and cell lysate 48
hours after infection using a human IL-12 (P70) OptEIA
ELISA (Pharmingen, San Jose, CA) assuming equal immu-
noreactivity as compared with the human p40/p35 het-
erodimer. Cells were lysed using 150 µl of culture lysis
reagent (Promega, Madison, WI) according to the manu-
facturers protocol and IL-12 quantified as previously
described.
Human colon cancer biopsies were infected with either
Ad.3r-luc or Ad.hscIL12 for 4 hours followed by incuba-
tion in HGDMEM supplemented with certified tetracy-
cline free fetal bovine serum (Clontech, Palo Alto, CA),
1% L-glutamine and 1% penicillin/streptomycin (Gibco)
in the presence or absence of Doxycycline (2 µg/ml) for 48
hours. IL-12 was determined in the supernatant as
described.
Luciferase expression was quantified by measuring luci-
ferase activity in 20 µl of cell culture supernatant with a
Bertold LB9507 luminometer and luciferase assay sub-
strate (Promega). Standard curves were generated using
recombinant firefly luciferase (Promega) diluted with
CCLR to concentrations from 1 pg/ml to 300 ng/ml and a
two-phase exponential association curve fitting was per-
formed due to saturation at higher concentrations using
the Prism software package (GraphPad Software, Inc, San
Diego, CA).
SDS-PAGE and immunoblotting
Cell lysates were resuspended in laemmli loading buffer
and separated using gel electrophoresis (Nu PAGE Novex
Bis-Tris Gel, Invitrogen). After blotting on Hybound-P
PVDF membranes (Amersham, Buckinghamshire, UK),
proteins were labeled with anti-β-actin (Sigma, St. Louis,
MI) and anti-TetR (Clontech) monoclonal antibodies.
Blots were then incubated with a peroxidase-linked sheep
anti-mouse secondary antibody (Amersham) and pro-
teins visualized through chemiluminescence by an ECL
Western blotting detection Kit (Amersham).
Bioassay
In order to characterize the bioactivity of virally expressed
human single-chain IL-12, human peripheral blood
mononuclear cells (MNCs) were purified from whole
blood after written consent and in accordance with
national ethical guidelines, following the LeucoSep-pro-
cedure (Greiner, Frickenhausen, Germany). Cell culture
bottles were coated with anti-human CD3 antibodies (10
µg/ml in PBS, #MAB100, R&D Systems, Minneapolis,
MN) and separated MNC were then incubated in the pres-
ence of an anti-human CD28 antibody (#AF-342-PB,
R&D Systems) at 0.5 µg/ml for three days. Prestimulated
MNC were seeded into 96 well plates at 4 × 104 cells/well
and incubated in 125 µl with various concentrations of IL-
12 either from adenovirally infected HT29 cell culture
supernatant or WHO reference standard (#95/544,
NIBSC, Herfordshire, UK). 24 hours later human inter-
feron-γ was quantified in cell free supernatant using a
human IFN-γ OptEIA ELISA (Pharmingen).
FACS-analysis
CD3- and CD28-prestimulated MNC were seeded into 6
well plates at 106 cells/well and incubated with different
IL-12 preparations at 100 pg/ml for 24 hours. 4 hours
after the addition of IL-12 the golgi apparatus was blocked
by brefeldin A (BFA) to prevent the export of newly syn-
thesized INF-γ. Cells were then labeled utilizing the Fas-
timmune Intracellular Cytokine Detection Kit (#346049,
Becton-Dickinson Biosciences, San Jose, CA). Briefly, cells
were washed in PBS containing 0.5% fetal bovine serum
and 0.1% NaN3 and resuspended in 0.5 ml FACS-Perm
prior to incubation at room temperature for 10 minutes.
Permeable cells were then stained with 20 µl of a DB Fas-
timmune anticytokine antibody solution (Anti-Hu-IFN-γ
FITC/CD69PE/CD8PerCP-Cy5.5/CD3APC) for 30 min-
utes, washed and fixated in PFA (1% paraformaldehyde in
PBS). Intracellular cytokine expression was performed by
FACScalibur flow cytometry (BD Biosciences) and ana-
lyzed by cellquest software.
Immunohistochemistry
Frozen sections of normal colon tissue and colon cancer
tissue with a thickness between 5 and 10 microns were
dried on coated slides at room temperature over night.
After fixation with 4% paraformaldehyde for 10 minutes
and incubation with 1% FCS for 30 minutes at room tem-
perature, sample sections were then incubated with the
mouse IgG1 monoclonal antibody Anti-CAR (clone RmcB,BMC Biotechnology 2007, 7:35 http://www.biomedcentral.com/1472-6750/7/35
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Upstate, NY) at 1 µg/ml in TBS supplemented with 1%
fetal bovine serum for 1 hour at room temperature. Sam-
ples were incubated for 30 minutes at room temperature
with rabbit anti-mouse IgG at 5 µg/ml. Immunostaining
according to the alkaline phosphatase/anti-alkaline phos-
phatase (APAAP) protocol was done by incubating the
sections with a mouse monoclonal APAAP complex
(Dako, dilution 1:50) for 30 minutes at room tempera-
ture. The enzyme reaction was then detected by new
fuchsin (Merck, Darmstadt, Germany), naphthol AS-BI
(Sigma) and levamisol (Sigma) and sections were finally
counterstained with hematoxylin.
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